Table 1.
Clinical characteristics of patients with Crohn’s disease and the control group
| Endoscopic Remission n = 27 |
Mild activity n = 21 |
Moderate to severe activity n = 32 |
P value | |
|---|---|---|---|---|
| Gender: | ||||
| Male | 11 (40.7%) | 15 (71.4%) | 16 (50.0%) | |
| Female | 16 (59.3%) | 6 (28.6%) | 16 (50.0%) | |
| Age (P 25–75) | 40,0 (29.0–50.0) | 41 (23.5–50.0) | 32,5 (24–36.8) | 0.102* |
| Montreal Classification | n (%) | n (%) | n (%) | |
| Age at diagnosis | ||||
| A1 (≤16 years) | 3 (11.1) | 1 (4.8) | 4 (12.5) | 0.149** |
| A2 (17–40) | 16 (59.3) | 15 (71.4) | 25 (78.1) | |
| A3 (>40 years) | 8 (29.6) | 5 (23.8) | 3 (9.4) | |
| Disease Phenotype | ||||
| B1 | 5 (18.5) | 4 (19.0) | 11 (34.4) | |
| B1p | 5 (18.5) | 6 (28.6) | 9 (28.1) | |
| B2 | 8 (29.7) | 5 (23.8) | 9 (28.1) | 0.342** |
| B2p | 2 (7.4) | 1 (4.8) | 1 (3.1) | |
| B3 | 5 (18.5) | 4 (19.0) | 0 (0) | |
| B3p | 2 (7.4) | 1 (4.8) | 2 (6.3) | |
| Location of disease | ||||
| L1 | 10 (37.0) | 8 (38.1) | 7 (21.9) | |
| L2 | 4 (14.8) | 4 (19.0) | 8 (25.0) | |
| L3 | 11 (40.8) | 8 (38.1) | 17 (53.1) | 0.628** |
| L1+ L4 | 2 (7.4) | 1 (4.8) | 0 (0) | |
| Medication | ||||
| 5-ASA | 14 (51.9) | 12 (57.1) | 14 (43.8) | |
| Thiopurine | 19 (70.3) | 14 (66.7) | 20 (62.5) | |
| Anti-TNF | 6 (22.2) | 0 (0) | 11 (34.4) | |
| Antibiotics | 4 (14.8) | 9 (42.9) | 2 (6.3) | |
| Prednisone | 9 (33.3) | 7 (33.3) | 19 (59.4) | |
| Methotrexate | 0 (0) | 0 (0) | 1 (3.1) | |
| Tacrolimus | 0 (0) | 0 (0) | 1 (3.1) | |
P25: 25thpercentile; P75: 75thpercentile; Significant p value: p < 0.05. *Kruskal-Wallis Test; **Fisher Exact Test. Age at diagnosis: A1: below 16 years of age; A2: between 17 and 40 years of age; A3: above 40 years of age. Location: L1: ileum; L2: colon; L3: ileocolonic; L4: upper gastrointestinal tract. Behaviour: B1: inflammatory; B2: stenosing; B3: penetrating; p = perianal; Anti-TNF (infliximab, adalimumab); Antibiotics (metronidazole, ciprofloxacin)